Cancer information / Cancer types / Lung / Treatment / Targeted therapy

American Cancer Society. (2016, May). Lung Cancer (Non-Small Cell). Retrieved from:

Cancer Care Ontario. Drug Formulary. Toronto, ON: Cancer Care Ontario.

Detterbeck FC, Decker RH, Tanoue L, Lilenbaum RC. Non-small cell lung cancer. DeVita VT Jr, Lawrence TS, Rosenberg SA. (2015). Cancer: Principles and Practice of Oncology. (10th Edition). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 41: 495-535.

Drugs and Health Products, Health Canada. (2017, August 27). Regulatory Decision Summary: Xalkori. Retrieved from:

Ellis PM, Coakley N, Feld R, Kuruvilla S, Ung YC. Use of the epidermal growth factor receptor inhibitors gefitinib (Iressa), erlotinib (Tarceva), afatinib, dacomitinib or icotinib in the treatment of non-small cell lung cancer: a clinical practice guideline. (2014, May 8). Evidence-Based Series (EBS) and Practice Guidelines (PG). Toronto, ON: Cancer Care Ontario. No.: 7-9 Version 2.

Health Canada. (2018, June 5). Regulatory Decision Summary - Zykadia. Retrieved from:

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (Version 4.2016). Retrieved from:

Princess Margaret Cancer Centre. (2015, September). Princess Margaret Cancer Centre Clinical Practice Guidelines: Lung Cancer. Retrieved from:

Saskatchewan Cancer Agency. (2015, April 1). Provincial Non-Small Cell Lung Cancer Treatment Guidelines. (Updated Edition).

VanderMeer R, Chambers, S, Van Dam A, Cutz JC, Goffin JR. Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care?. (2015). Current Oncology. 22(4): 272-278.